AGREEMENT AND PLAN OF MERGER among: AURIS MEDICAL HOLDING LTD., an exempted company incorporated under the laws of Bermuda; AURIS MEDICAL INC., an Illinois corporation; TRASIR THERAPEUTICS, INC., a Delaware corporation; andAgreement and Plan of Merger • June 3rd, 2021 • Auris Medical Holding Ltd. • Pharmaceutical preparations • Delaware
This Agreement And Plan Of Merger (this “Agreement”) is entered into as of June 1, 2021, among Auris Medical Holding Ltd., an exempted company incorporated under the laws of Bermuda (“Parent”), Auris Medical Inc., an Illinois corporation and wholly owned subsidiary of Parent (“Subco”), Trasir Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the Company Stockholders (as defined below).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***]”. EXCLUSIVE LICENSE AGREEMENT...Exclusive License Agreement • June 3rd, 2021 • Auris Medical Holding Ltd. • Pharmaceutical preparations • Missouri
This agreement (“Agreement”) is made and entered into, effective as of 12/11/2020 (“Effective Date”) by and between: Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as “WU”); and Trasir Therapeutics, Inc. a corporation organized and existing under the laws of the State of Delaware, having its principal offices at 618 Vanderbaker Road, Temple Terrace, FL 33617 (hereinafter referred to as “Licensee”) and the following correspondence addresses, each a “Party” or collectively the “Parties” of this Agreement:
